SCHEMBL8438353

SCHEMBL8438353

COC(=O)C1=C(C)N(C)C(C)=C(C(C)=O)C1c1ccc(Cl)c(Cl)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 4/20 0.65
HPGD P15428 2/20 0.65
KDM4E B2RXH2 1/20 0.65
TSHR P16473 6/20 0.59
HSD17B10 Q99714 2/20 0.59
LMNA P02545 3/20 0.57
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
GAA P10253 2/20 0.48
GPBAR1 Q8TDU6 1/20 0.45
ALDH1A1 P00352 1/20 0.45
CASP1 P29466 1/20 0.45
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43
TP53 P04637 1/20 0.42
SLC6A4 P31645 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8437322 0.91 NPSR1 (0.49) NPSR1HPGDKDM4ETSHRHSD17B10
SCHEMBL8440699 0.86 NPSR1 (0.57) NPSR1HPGDKDM4ETSHRHSD17B10
SCHEMBL8345995 0.85 NPSR1 (0.89) NPSR1HPGDKDM4ETSHRHSD17B10
SCHEMBL11864469 0.85 NPSR1 (0.56) NPSR1HPGDKDM4ETSHRHSD17B10
SCHEMBL8441182 0.83 NPSR1 (0.44) NPSR1HPGDKDM4ETSHRHSD17B10
SCHEMBL8441842 0.80 TSHR (0.68) NPSR1HPGDKDM4ETSHRHSD17B10
SCHEMBL9120515 0.80 NPSR1 (0.62) NPSR1HPGDKDM4ETSHRHSD17B10
SCHEMBL11863359 0.80 TSHR (0.67) NPSR1HPGDKDM4ETSHRHSD17B10
SCHEMBL14986926 0.79 NPSR1 (1.00) NPSR1HPGDKDM4ETSHRHSD17B10
SCHEMBL8602746 0.78 TSHR (0.58) NPSR1HPGDKDM4ETSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0717036-B1 Use of 5-acyl-1,4-dihydropyridines for the treatment of diseases of the CNS BAYER AG (DE) 1999-03-17 EP claimed
US-5646166-A POTASSIUM CHANNEL MODULATORS, TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 1997-07-08 US claimed